R&D News | pharmaphorum

News

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRe

News

Novo Nordisk achieve headline results with icodec insulin

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 pha

News

Roche gets FDA approval for HER2 breast cancer diagnostic

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

News

Positive phase 3 results for Zealand Pharma's glepaglutide

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the

News

Amylyx ALS drug draws criticism over $158,000 price tag

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next da

News

Fatty liver, liver steatosis. Photomicrograph showing large vacuoles of triglyceride fat accumulated inside liver cells, it occurs in alcohol overuse, under action of toxins, in diabetes

Intercept hit hard as NASH trial misses the mark

Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial.

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Novo Nordisk achieve headline results with icodec insulin

Roche gets FDA approval for HER2 breast cancer diagnostic

Positive phase 3 results for Zealand Pharma's glepaglutide

Amylyx ALS drug draws criticism over $158,000 price tag

Intercept hit hard as NASH trial misses the mark

Moderna's Q1 revenues rocket, thanks to ex-US sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks